Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 25 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

This approval makes Zydus the first company to receive final approval for these generic tablets. The product will be manufactured at Zydus's facility in Ahmedabad and is set to launch immediately in the US market. Gabapentin is used for managing Postherpetic Neuralgia, with significant annual sales in the US market.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 25, 2024, titled "Zydus receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases